Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...

Vivani Medical (VANI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

About Cortigent, Inc. Cortigent, Inc., formerly Second Sight Medical Products and a wholly owned subsidiary of Vivani, is developing brain implant devices to help people recover critical body ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

HC Wainwright reduced their FY2024 earnings estimates for shares of Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company ...

Jane Street Group LLC purchased a new stake in Vivani Medical in the 4th quarter valued at $66,000. Wealthedge Investment Advisors LLC acquired a new stake in Vivani Medical in the 4th quarter ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...